2 PhD positions in GENEGUT
2 PhD Positions in “Delivery of RNA Therapies to Cells and preclinical models” APC Microbiome Ireland, School of Medicine and School of Biochemistry and Cell
THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.
GENEGUT has one primary ambition: to create a first-of-its-kind, game-changing treatment for ileal Crohn’s Disease, addressing a significant unmet medical need, by making major advances in RNA-delivery technology to inflamed sites in the gut following oral administration.
The delivery of RNA will be enabled by a combination approach where novel biomaterials designed to overcome the barriers in the gastrointestinal tract, are synthesized into nanoparticles (NP) which encapsulate the RNA. Using an industry partner’s emergent capsule platform technology, the RNA is orally administered and locally tackles the inflammation in the intestinal tissue, avoiding systemic side effects.
2 PhD Positions in “Delivery of RNA Therapies to Cells and preclinical models” APC Microbiome Ireland, School of Medicine and School of Biochemistry and Cell
Coordinated by the University College Cork, GENEGUT brings together 9 Partners from 8 different countries to develop a revolutionary treatment for CD
Affecting about 3 million people in Europe alone, Inflammatory Bowel Disease (IBD) has a drastic impact on the quality of life – and new therapies are urgently needed